Venture Capital

With a 25-year tenure, new CEO Ann Fairchild will leverage her strategic and legal expertise to steer Siemens through America's industrial revival.

In a deal valued over $100M, Teamworks is absorbing PFF's elite football data to forge a unified AI platform, reshaping operations for NFL and NCAA teams.

With a new Chief Strategy Officer from Lockheed Martin, Sierra Space signals a major push for M&A, franchise wins, and dominance in the defense-tech market.

With backing from CPG giants, the creatine gummy maker plans to use its new $20M funding to make the supplement a daily wellness staple for everyone.

A new partnership aims to disrupt the vacation rental market by eliminating host fees, putting pressure on industry giants like Airbnb and Vrbo.

Tethered drone leader Hoverfly partners with Korea's KRM to tackle a critical U.S. defense vulnerability: the nation's reliance on Chinese drone parts.

The visual app giant's pivot to AI agents drove a 65% profit surge and captured high-value global markets, redefining its future and business model.

The new AI model generates multi-shot films with sound from a single prompt, challenging rivals and pushing deeper into enterprise automation.

The purchase of IronHQ marks Perseus's 11th dealer software deal, reinforcing a broader strategy of dominating niche vertical software markets.

The biotech firm's oversubscribed funding round will accelerate its universal flu shot and a diverse pipeline targeting cancer, malaria, and Alzheimer's.

In a strategic move to dominate the AI infrastructure boom, AVAIO Digital has hired industry pioneer Jason Norado to execute its multi-gigawatt expansion.

Phase 2 data for HRS/BHB-1893 show rapid efficacy and a simplified regimen, signaling a potential new era for treating hypertrophic cardiomyopathy.

German CDMO Vetter wins a prestigious, client-voted award, underscoring its pivotal role and massive €2 billion investment in the world of injectable biologics.

A new drug not only reduces osteoarthritis pain significantly but may also be the first to modify the disease itself, a landmark study in The Lancet reveals.

South Korean AI chip leader Rebellions raises $400M, launching full-stack AI systems to redefine efficient inference and spearhead a global expansion.

A $15M grant fuels a revolutionary therapy for a fatal childhood disease, turning patients' own cells into 'living biofactories' to fight MPS I.

Amid a tough biotech market, the firm extends its cash runway to 2027, accelerating development of its promising rademikibart treatment for respiratory diseases.

After a major capital overhaul, PAVmed pivots to growth, advancing cancer diagnostics, remote monitoring, and a relaunched device portfolio.

As millions grapple with Cannabis Use Disorder, a small biotech's lead drug enters Phase 3 trials, promising the first-ever FDA-approved treatment.

Starcloud is now Y Combinator's fastest unicorn. Its audacious plan to build data centers in orbit has attracted top VCs and sparked a new space race for AI.